首页 | 本学科首页   官方微博 | 高级检索  
     

4种糖皮质滴眼液治疗急性前葡萄膜炎的成本-效果分析
引用本文:哈力,叶文杰,胡宝荣. 4种糖皮质滴眼液治疗急性前葡萄膜炎的成本-效果分析[J]. 中国药房, 2012, 0(6): 495-497
作者姓名:哈力  叶文杰  胡宝荣
作者单位:[1]哈尔滨医科大学附属第一医院,哈尔滨150001 [2]哈尔滨医科大学药学院,哈尔滨150086
摘    要:目的:比较4种糖皮质滴眼液治疗急性前葡萄膜炎的成本-效果。方法:将195例急性前葡萄膜炎患者分为A(复方新霉素多粘菌素滴眼液)、B(氟米龙滴眼液)、C(醋酸泼尼松龙滴眼液)、D(妥布霉素/地塞米松滴眼液)4组,4组患者都使用相同剂量的同种散瞳药与抗生素滴眼液作为辅助用药,各组结果运用药物经济学原理进行成本-效果分析。结果:在平均疗程内,A、B、C、D组成本分别为42.10、45.40、73.80、80.00元;有效率分别为93.1%、94.0%、96.8%、90.6%;在有效率不变的情况下分别下调各组药品成本价格10%,对最终结果无影响;B、C、D组药品价格需要分别下调6.83%、40.96%、49.04%,方可获得与A组相同的成本-效果比。结论:从药物经济学角度考虑,A方案较佳。

关 键 词:急性前葡萄膜炎  糖皮质滴眼液  药物经济学  成本-效果分析

Cost-effectiveness Analysis of 4 Kinds of Corticosteroid Eye Drops in the Treatment of Acute Anterior Uveitis
HA Li,HU Bao-rong. Cost-effectiveness Analysis of 4 Kinds of Corticosteroid Eye Drops in the Treatment of Acute Anterior Uveitis[J]. China Pharmacy, 2012, 0(6): 495-497
Authors:HA Li  HU Bao-rong
Affiliation:(The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China) YE Wen-jie(College of Pharmacy, Harbin Medical University, Harbin 150086, China)
Abstract:OBJECTIVE: To compare the cost-effectiveness of 4 kinds of corticosteroid eye drops in the treatment of acute anterior uveitis. METHODS: 195 cases of acute anterior uveitis were divided into group A (Compound fradiomycin polymyxin B eye drops), group B (Fluorometholone eye drops), group C (Prednisolone acetate eye drops), group D (Tobramycin and dexametha- sone eye drops). Those 4 groups were given same dose of same mydriatic and antibiotic eye drops as adjunctive treatment. Cost-effectiveness analysis of each group was conducted using pharmacoeconomics. RESULTS: In an average course of the treatment, the costs of 4 groups were 42.10, 45.40, 73.80 and 80.00 yuan, respectively. Tkle effective rates of 4 groups were 93.1%, 94.0%, 96.8% and 90.6% respectively. If the effective rate stayed at the same level and drug price of 4 groups decrease by 10% at the same time, it makes no difference to at the final result. Drug price of scheme B, C, D need to be decreased by 6.83%, 40.96%, 49.04%, respectively, so that their cost-effectiveness ratios can be same to that of scheme A. CONCLUSION: In perspective of pharmacoeconomics, scheme A is the best one.
Keywords:Acute anterior uveitis  Corticosteroid eye drops  Pharmacoeconomics  Cost-effectiveness analysis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号